Cullinan Therapeutics to Participate in Immunity and Inflammation Forum Discussion

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. Chief Medical Officer Jeffrey Jones, M.D., M.B.A., is scheduled to participate in a fireside chat on Tuesday, September 16, 2025, at 9:30 a.m. ET. The discussion will likely focus on the company's pipeline of therapies for autoimmune diseases and cancer.

The Stifel forum is a virtual event bringing together experts in the field of immunology and inflammation. It provides a platform to discuss the latest advancements and therapeutic approaches in treating these conditions.

Cullinan Therapeutics is a biopharmaceutical company focused on developing targeted therapies. The company strategically builds a portfolio of clinical-stage assets aimed at inhibiting disease drivers or harnessing the immune system to combat autoimmune diseases and cancer.

A webcast of the fireside chat will be made available on the company's investor relations website. Cullinan Therapeutics aims to create new standards of care for patients with its differentiated therapeutic options.